145 related articles for article (PubMed ID: 37433196)
1. 4-1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T.
Shen X; Zhang R; Nie X; Yang Y; Hua Y; Lü P
Cancer Biother Radiopharm; 2023 Sep; 38(7):431-444. PubMed ID: 37433196
[TBL] [Abstract][Full Text] [Related]
2. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.
Chin SM; Kimberlin CR; Roe-Zurz Z; Zhang P; Xu A; Liao-Chan S; Sen D; Nager AR; Oakdale NS; Brown C; Wang F; Yang Y; Lindquist K; Yeung YA; Salek-Ardakani S; Chaparro-Riggers J
Nat Commun; 2018 Nov; 9(1):4679. PubMed ID: 30410017
[TBL] [Abstract][Full Text] [Related]
3. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
[TBL] [Abstract][Full Text] [Related]
4. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
Li G; Boucher JC; Kotani H; Park K; Zhang Y; Shrestha B; Wang X; Guan L; Beatty N; Abate-Daga D; Davila ML
JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232281
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
Chester C; Sanmamed MF; Wang J; Melero I
Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
[TBL] [Abstract][Full Text] [Related]
6. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
7. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy.
Liu G; Luo P
Front Immunol; 2023; 14():1208788. PubMed ID: 37334375
[TBL] [Abstract][Full Text] [Related]
8. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis.
Etxeberria I; Glez-Vaz J; Teijeira Á; Melero I
ESMO Open; 2020 Jul; 4(Suppl 3):e000733. PubMed ID: 32611557
[TBL] [Abstract][Full Text] [Related]
9. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
10. Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent.
Gomes-Silva D; Mukherjee M; Srinivasan M; Krenciute G; Dakhova O; Zheng Y; Cabral JMS; Rooney CM; Orange JS; Brenner MK; Mamonkin M
Cell Rep; 2017 Oct; 21(1):17-26. PubMed ID: 28978471
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
Front Immunol; 2020; 11():539654. PubMed ID: 33281809
[TBL] [Abstract][Full Text] [Related]
12. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
Mardiana S; John LB; Henderson MA; Slaney CY; von Scheidt B; Giuffrida L; Davenport AJ; Trapani JA; Neeson PJ; Loi S; Haynes NM; Kershaw MH; Beavis PA; Darcy PK
Cancer Res; 2017 Mar; 77(6):1296-1309. PubMed ID: 28082401
[TBL] [Abstract][Full Text] [Related]
13. 4-1BB chimeric antigen receptors.
Campana D; Schwarz H; Imai C
Cancer J; 2014; 20(2):134-40. PubMed ID: 24667959
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.
Li S; Zhang J; Wang M; Fu G; Li Y; Pei L; Xiong Z; Qin D; Zhang R; Tian X; Wei Z; Chen R; Chen X; Wan J; Chen J; Wei X; Xu Y; Zhang P; Wang P; Peng X; Yang S; Shen J; Yang Z; Chen J; Qian C
Br J Haematol; 2018 May; 181(3):360-371. PubMed ID: 29637550
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.
Trüb M; Uhlenbrock F; Claus C; Herzig P; Thelen M; Karanikas V; Bacac M; Amann M; Albrecht R; Ferrara-Koller C; Thommen D; Rothschield S; Savic Prince S; Mertz KD; Cathomas G; Rosenberg R; Heinzelmann-Schwarz V; Wiese M; Lardinois D; Umana P; Klein C; Laubli H; Kashyap AS; Zippelius A
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616554
[TBL] [Abstract][Full Text] [Related]
16. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
Müller D; Frey K; Kontermann RE
J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of cancer with 4-1BB.
Vinay DS; Kwon BS
Mol Cancer Ther; 2012 May; 11(5):1062-70. PubMed ID: 22532596
[TBL] [Abstract][Full Text] [Related]
18. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy.
Claus C; Ferrara-Koller C; Klein C
MAbs; 2023; 15(1):2167189. PubMed ID: 36727218
[TBL] [Abstract][Full Text] [Related]
19. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
[TBL] [Abstract][Full Text] [Related]
20. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
